Dr Paula Ellenberg
Laboratory Manager
Working groups
Background
Dr Paula Ellenberg is a mid-career researcher with 12 years of post-doctoral experience in the field of Retrovirus pathogenesis. After being awarded her PhD in 2008 by the University of Buenos Aires for her studies on the Arenavirus Junin, she moved to Australia to join several multidisciplinary teams focused on Retrovirus biology with the primary goal of unmasking potential drug targets to eliminate HIV-1 and HTLV-1. Her studies resulted in 18 peer-reviewed publications in the virology space.
Dr Ellenberg is skilled in viral molecular cloning, including the introduction of genetic tags and mutations into the retroviral genome. Further, she has extensive experience in experimental design and implementation of retrovirus infection of primary cells.
Qualifications
- 2008 PhD from University of Buenos Aires
Awards
- 2024: Miller Foundation Biomedical Research Travel Fellowship
Positions
- Senior Research Fellow- Purcell Lab-Doherty Institute. University of Melbourne
Burnet publications
View 7 moreThe science at HIVR4P 2024: The era of choice in biomedical HIV prevention
Journal of the International AIDS Society
Beatriz Grinsztejn et al
Targeting HIV-1 Reverse Transcriptase Using a Fragment-Based Approach
Molecules
Mahta Mansouri et al
Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists
AIDS Research and Human Retroviruses
Jacqueline K. Flynn et al
Current projects
View 5 moreEVE-M®: enhancing the vaginal environment and microbiome
The vaginal microbiome is a key determinant of a women’s sexual and reproductive health. There is an unmet need for effective non-antibiotic-based strategies to target bacterial vaginosis and its adverse sequelae.
Vaginal microbiota and HIV susceptibility
Projects are available to determine the direct anti-HIV and bactericidal mechanisms of vaginal microbiota metabolites.
Discovery of a new drug class for HIV treatment and prevention
Drug resistance, toxicity and intolerance could exhaust antiretroviral drug options for HIV treatment and prevention, with few new drug classes in the pipeline.
